4WF
/ Esperion Therap
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
November 05, 2020
"https://t.co/av87ie4WFk"
(@ellyanaxx)
November 05, 2020
"https://t.co/av87ie4WFk"
(@ellyanaxx)
September 22, 2020
"Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA https://t.co/jBEp4WFe4L"
(@NewsFromBW)
March 18, 2014
Esperion Therapeutics: Annual Report 2013
(Esperion Therapeutics)
- Anticipated patent expiry in US on Jul 12, 2030; Anticipated expiry of several issued US patents between 2021-2030
Anticipated patent expiry • Dyslipidemia
August 21, 2019
The Incorporation of Oxidation Resistant ApoA1-4WF in Adeno-Associated Viral and Lentiviral Gene Vectors With Robust Cholesterol Efflux in vitro
(AHA 2019)
- "ApoA1-4WF transgene expression can be achieved with both AAV and lentiviral vector systems with retention of RCT under conditions of oxidative stress."
Preclinical • APOA1
July 30, 2019
"See a new #NSCLC activity via @PeerView, @benlevylungdoc, @hosseinborghaei, and Professor Tony Mok #ASCO19 #CME https://t.co/Mf4WFeoj0J"
(@SpeakJen)
July 22, 2019
"The sugar substitute xylitol may help you lose weight, but it can be deadly for your dog, @US_FDA warns. https://t.co/Qdr4WFrFFY"
(@AVMAvets)
May 18, 2019
Stent-based Gene Therapy of Restenosis with an Oxidation-resistant Apolipoprotein A1 Mutant
(ATVB-PVD-GPM 2019)
- "These findings suggest that 4WF mutated apoA1 is a promising candidate for stent based gene therapy of ISR in the HCD pig model."
May 16, 2019
"Bluebird Network Celebrates Missouri Network Alliance’s 20th Anniversary https://t.co/IcjT9a4WFo"
(@NewsFromBW)
1 to 9
Of
9
Go to page
1